ABL1 and acute lymphoblastic leukemia: It is well documented that NGS is markedly superior to SS in terms of sensitivity, and can additionally allow straightforward identification of the most frequent compound mutations.26, 27, 28, 29, 30, 31, 32, 33, 34 However, very few data are available on the clinical impact of BCR‐ABL1 KD mutation testing by NGS in patients with Ph+ ALL, and this does not allow the formulation of evidence‐based recommendations.